Michelle Kreke, Ph.D., has dedicated her career to advancing autologous and allogeneic cell therapies, with over 20 years of experience in biotech and pharma. She has a broad scientific and technical background, including analytical and process development, clinical manufacturing operations, chemistry, manufacturing and controls (CMC), and pre-clinical development, including in vitro and in vivo pharmacology and toxicology. During her career, Michelle has advanced more than a dozen cell therapy products through industry-sponsored investigational new drug (IND) applications, achieving FDA approvals within 30 days.